Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe 2.5mg dose of Mounjaro is not designed to produce significant weight loss. It is a tolerability dose — its job is to let your body adjust to tirzepatide before the real treatment begins. Most people wonder, quite reasonably, whether the starting pen is doing anything at all. The short answer is: not much yet, and that is exactly how it should be. Mounjaro is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is right for you before any treatment is issued.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide activates two gut-hormone receptors (GIP and GLP-1) that regulate appetite and slow the rate at which the stomach empties. At 2.5mg, that activation is gentle. The dose was not included in SURMOUNT-1's efficacy analysis because Eli Lilly did not intend it as a therapeutic dose at all. The four-week starter period exists to give your digestive system time to adapt, which meaningfully reduces the nausea and stomach upset that can hit if someone jumps straight to a higher dose.
So if you are four weeks in and the scales have barely moved, please do not read that as failure. A question our prescribers hear regularly is whether the starter pen is working, and the honest answer is that it is working, just not on appetite yet. It is working on tolerability. That is a worthwhile job.
You can read a broader overview of how Mounjaro fits into a weight-management plan on our Mounjaro information page.
A small amount of incidental weight loss is possible during the 2.5mg period, partly because people on any new weight-management programme tend to pay closer attention to food choices, and partly because even a modest slowing of gastric emptying can reduce snacking. But you should not expect the kind of results that clinical evidence associates with tirzepatide. The SURMOUNT-1 data, published in the New England Journal of Medicine, found average weight reductions of roughly 15–20% at the higher doses over 72 weeks, figures achieved by thousands of participants titrated well beyond the starter dose.
If someone tells you they lost substantial weight on 2.5mg alone, individual factors may be at play, but the population-level evidence simply does not support expecting that outcome at the starting dose. Managing expectations here protects you from unnecessary disappointment and from abandoning treatment before it has had a fair chance.
Whether the 2.5mg dose is doing enough for your specific situation is ultimately a clinical question; your prescriber will review your progress before recommending any titration step.
After roughly four weeks at 2.5mg, the standard path is an increase to 5mg, and this is where most people notice their appetite beginning to shift. Meals feel more filling, the urge to snack eases, and the habit of eating past fullness becomes easier to resist. The evidence around the 5mg dose is considerably stronger than at 2.5mg, and the step up is a meaningful clinical moment.
From 5mg the schedule continues in approximately four-week increments (7.5mg, 10mg, 12.5mg, 15mg) though titration speed and the dose you ultimately stay at depend on how well you tolerate each level and how your weight responds. Your prescriber reviews this before any increase; it is never automatic. For a closer look at how the timeline develops, this page on when 5mg begins to take effect walks through what to expect as the dose builds.
The NHS's patient information on tirzepatide gives a reliable overview of the dose schedule and what to discuss with your prescriber at each stage.
Almost certainly yes, provided you are tolerating it. The whole point of the starter dose is to earn you access to the doses where the medicine does its real work. Stopping after the first pen because the scales have not moved is a bit like stopping a course of antibiotics after two days because you still feel unwell.
That said, if you are experiencing side effects severe enough to affect daily life, or if you have any concerns about how the medicine is sitting with you, that is a conversation for your prescriber rather than a reason to push through silently. Titration can be slowed; that is a clinical tool, not a defeat. You can also read about what to do if a dose delivery feels incomplete, since pen technique questions are common in the early weeks.
On cost: some people consider stopping early partly because of the expense of private treatment. Our guide to Mounjaro pricing in the UK gives honest context on what private treatment costs and what legitimate providers include. And if you are ready to talk to a prescriber about whether Mounjaro is right for you, starting a free consultation is the next step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.